New Delhi: Dr. Reddy’s Laboratories’ shares are in focus as the price jumped on June 5, 2025. The company’s shares surged 4 percent to Rs 1,303 and became the top gainer of Nifty 50 today.
The pharma share has surged 26 percent from its one-year low. Recently, the pharma company stocks were under pressure after US President Donald Trump’s tariff announcements.
The shares of Dr. Reddy’s increased after it announced a strategic partnership with Alvotech. Both the companies have agreed to develop a biosimilar drug, which will be a copy of the popular anti-cancer drug Keytruda (pembrolizumab).
Dr. Reddy’s share price target
Brokerage firm HSBC has upgraded its rating for Dr. Reddy’s shares range from ‘Hold’ to ‘Buy’. The brokerage increased the share price target from Rs 1,235 to Rs 1,445. HSBC also mentioned that Dr. Reddy’s Semaglutide drug can rapidly help the company’s earnings and profits surge in the coming time.
Dr. Reddy’s shares jumped 9 per cent in the last one month, while the Nifty 50 index has seen a rise of only 1 per cent.
The counter gained 26 per cent from its one-year low level.
In a period of one year, the stock touched a low of Rs 1,020 and a high of Rs 1,421.05.
What is Keytruda (pembrolizumab)?
Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. It is being labelled as a blockbuster immunotherapy drug with global sales of $29.5 billion in 2024. Dr. Reddy’s and Alvotech have collaborated to develop, manufacture and sell its biosimilar edition worldwide.
Dr Reddy’s Laboratories released a statement which stated that the Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for international markets.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds and crypto assets.)
Brokerage firm HSBC has set a target price of Rs 1445 apiece for Dr. Reddy’s shares. The stock jumped after Dr Reddy’s and Alvotech joined hands to develop biosimilar for cancer treatment. Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
